NKTR earnings analysis
What we found in NKTR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Nektar’s Q2 2026 results were mixed: revenue of $10.131 million declined approximately 7.9% sequentially and year over year and missed consensus, while diluted EPS of negative $1.23 improved from negative $1.82 in Q1 and beat the negative $2.04 estimate. Liquidity was strong at approximately $1,023.4 million, supporting management’s stated runway through the third quarter of 2028, but the company reported an $85.5 million six-month net loss and continues to bear substantial costs and execution risk as rezpegaldesleukin advances into Phase 3. No numerical revenue or EPS guidance was provided; management referenced a first BLA submission in 2029.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Declined and Missed Estimates
- Q2 2026 revenue was $10.131 million, down approximately 7.9% from approximately $11 million in Q1 2026 and approximately 7.9% from approximately $11 million in Q2 2025. Revenue also missed the $10.536 million consensus estimate by 3.85%.
- EPS Loss Improved and Beat Consensus
- Diluted EPS was negative $1.23 versus negative $1.82 in Q1 2026 and negative $2.95 in Q2 2025, an improvement of $0.59 sequentially and $1.72 year over year. EPS beat the negative $2.04 consensus estimate by 39.71%.
- Gross Margin Remained 100%
- Gross margin remained 100.0% in Q2 2026, consistent with the 100.0% reported in each quarter from Q1 2025 through Q1 2026. Operating margin was not disclosed in the provided filing text.
- Liquidity Provides Extended Runway
- Cash and investments in marketable securities were approximately $1,023.4 million as of June 30, 2026. Management stated this liquidity is sufficient to meet requirements through at least the next 12 months and expects runway through the third quarter of 2028.
- Rezpegaldesleukin Entered Phase 3
- Nektar initiated the first two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, for rezpegaldesleukin in July 2026. The company intends to initiate the ZENITH-AA-1 global registrational trial in early 2027 and expects the first BLA submission in 2029.
- Phase 3 Advancement Increased R&D Spending
- The company reported a net loss of $85.5 million for the six months ended June 30, 2026. Research and development expense was $39.129 million in Q2 2026 as Nektar advanced its Phase 3 program.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Phase 3 Program Carries Significant Cost and Execution Risk
- Nektar now bears the development costs for rezpegaldesleukin after regaining full rights from Lilly in April 2023, while the program includes three global Phase 3 atopic dermatitis trials and a planned Phase 3 alopecia areata trial in early 2027. Failure or delay in these programs could materially impair the company despite $1,023.4 million of cash and investments.
- Reliance on Investigator-Sponsored Trials
- The company initiated a Phase 2 TrialNet study in May 2026 but does not control the design, conduct, timing, or reporting of investigator-sponsored trials. Inadequate or negative data from this study could delay development or prevent further advancement of rezpegaldesleukin.
- Pending Lilly and Securities Litigation
- Nektar faces a Lilly litigation trial scheduled for September 8, 2026, and a putative securities class action filed in March 2026 concerning alleged disclosures from February 2025 through December 2025. The company recorded no litigation liability as of June 30, 2026, but an unfavorable outcome could materially affect its financial condition.
- Single-Source PEG Reagent Dependence
- Following the sale of the Facility, Nektar is dependent on Gannet BioChem for PEG reagents used in manufacturing rezpegaldesleukin. The filing states that supply interruption or quality problems could delay clinical trials or increase costs.
- AI Use Creates New Compliance and Cyber Risks
- The company disclosed new or expanded risks from its use of artificial intelligence, including data leakage, intellectual-property claims, cybersecurity incidents, and evolving regulation. The EU AI Act has important sections scheduled to take effect in August 2026, potentially increasing compliance costs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.23
- Gross margin
- 100.0%
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management stated that cash and investments of approximately $1,023.4 million are expected to fund operations through at least the third quarter of 2028, and expects the first BLA submission for rezpegaldesleukin in 2029.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Nektar Therapeutics reported Q1 2026 with total revenue of $10.9 million, marking a slight increase of 3.85% compared to $10.5 million in Q1 2025. However, the company reported a larger EPS loss of -$1.82, which was…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NKTR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever